Laserfiche WebLink
c MER��E= SAFETY & HEALTH MANUAL <br />0.03.c. Are precautions taken to ensure that unadulterated specimens are obtained and correctly identified that meet <br />the following requirements: 1) Bluing agents in toilet tank and all water sources secure [§40.43(b)(1) and (2)]; 2) <br />Individual positively identified (photo ID, etc.) [§40.61(c)]; 3) Proper authority contacted if individual fails to arrive at <br />the assigned time [§40.61(a)]; 4) The donor shall remove any unnecessary outer garments. Purses or briefcases shall <br />remain with outer garments [§40.61(f)]; 5) Donor shall wash and dry his/her hands [§40.63(b)]; 6) To the greatest <br />extent possible, the collector must keep an employee's collection container within view of both himself/herself and the <br />employee between the time the employee has urinated and the specimen is sealed [§40.43(d)(2)]; and, 7) Any unusual <br />behavior noted on the CCF [§40.63(e)] <br />0.03.d. Are procedures being followed at the collection site after the specimen has been provided in compliance with <br />the requirements of §40.65 <br />0.03.e. Have provisions been made if the donor is unable to provide at least 45 milliliters of urine [§40.65(a)]7 <br />0.03.f. Are procedures in place for immediately collecting urine specimens under direct observation for the situations <br />identified in §40.67(c). As of August 31, 2009, verify that all collections for return -to -duty and follow-up testing were <br />performed under DER directed direct observation [§40.67(b)] <br />0.03.g. Are same gender collection personnel used if a collection is monitored under direct observation by non -medical <br />personnel [§40.69(g)] <br />0.03.h. Is the CCF properly executed by authorized collection site personnel upon receipt and transfer of a urine <br />specimen [§40.73(a)] <br />D.01.a. Verify drug testing laboratory used for all testing required by Part 40 and Part 199 is certified by the <br />Department of Health and Human Services (HHS) [§40.81(a) and §199.107(a)]. <br />D.01.c. Verify laboratory results are reported directly, and only, to the MRO at his or her place of business. Results <br />must not be reported to or through the DER or a service agent (e.g., C/TPA) [§40.97(b)]. <br />D.01.b. Verify drug testing laboratory only tests for the following five drugs or classes of drugs in a DOT drug test. (The <br />laboratories must not test "DOT specimens" for any other drugs): (a) Marijuana metabolites; (b) Cocaine metabolites; <br />(c) Amphetamines; (d) Opiate metabolites; and (e) Phencyclidine (PCP) [§40.3, §40.85 and §199.3]. <br />D.01.d. Verify laboratory testing the primary specimen will retain a specimen that was reported with positive, <br />adulterated, substituted, or invalid results for a minimum of one year. The specimen must be kept in secure, long-term, <br />frozen storage in accordance with HHS requirements [§40.99 and §199.111(a)]. <br />D.03.a. Verify laboratory retains all records pertaining to each employee urine specimen for a minimum of two years <br />and also keeps for two years, employer -specific data required in §40.111 [§40.109]. <br />D.03.1a. Verify laboratory transmits an aggregate statistical summary to the Company per Part 40, Appendix B, on a <br />semi-annual basis. <br />D.02.a. If the Company or C/TPA, used by the Company, has an aggregate of 2000 or more DOT -covered employees, <br />blind specimens are submitted to the laboratories used. If the Company or C/TPA has an aggregate of fewer than 2000 <br />DOT -covered employees, DOT does not require them to provide blind specimens [§40.103(a)]. <br />E.01.a. Verify that an MRO is designated or appointed by the Anti -Drug Plan [§199.109(a)]. <br />E.01.b. Verify that the MRO provides quality assurance reviews of the drug testing process, including ensuring the <br />review of the Custody and Control Form (CCF) on all specimen collections [§40.123(b)]. <br />E.01.c. Verify that the MRO performs the review functions required by §40.127 for negative drug test results received <br />from a laboratory, prior to verifying the result and releasing it to the Designated Employer Representative (DER). <br />E.01.d. Verify that the MRO performs the review functions required by §40.129 for confirmed positive, adulterated, <br />substituted, or invalid drug test results received from a laboratory, prior to verifying the result and releasing it to the <br />SECTION 42: Anti -Drug & Alcohol Misuse Prevention Plan Program I Page 45 of 49 <br />